Context: Individuals with glycated hemoglobin (HbA1c)-defined prediabetes (HbA1c value of 5.7-6.4%) and 1-hour plasma glucose Ն155 mg/dL during an oral glucose tolerance test have an increased risk of developing type 2 diabetes.
cations, and early detection of individuals at high risk for the disease is essential because the progression to diabetes is preventable through lifestyle-change interventions and/or pharmacological treatments (2, 3) . Prediabetes is a condition of dysglycemia defined by impaired fasting glucose and/or impaired glucose tolerance (4) . The prevalence of prediabetes is increasing worldwide, and the International Diabetes Federation has projected that 471 million people will have prediabetes by 2035 (1) . Diagnostic criteria for individuals at high risk for type 2 diabetes have changed over time (5) . In 2010, the American Diabetes Association (ADA) revised criteria for the diagnosis of categories at high risk for type 2 diabetes and recommended considering individuals with a glycated hemoglobin (HbA1c) values of 5.7-6.4% (39 -46 mmol/mol) as a new category of prediabetes in addition to impaired fasting glucose and impaired glucose tolerance (6) . Associations of prediabetes with organ damage usually considered as complications of type 2 diabetes, including nonalcoholic fatty liver disease (NAFLD), nephropathy, retinopathy, neuropathy, and cardiovascular disease, have been reported (7) (8) (9) (10) . In this context, the association between a prediabetes condition and NAFLD is clinically and pathophysiologically relevant. Indeed, NAFLD is the most common chronic liver disease, affecting up to 46% of the general population (11, 12) . NAFLD encompasses a spectrum of conditions ranging from simple steatosis, which is considered to be relatively benign, to inflammatory nonalcoholic steatohepatitis, which may progress to cirrhosis and, ultimately, to hepatocellular carcinoma (13, 14) . The liver has an important role in the maintenance of glucose homeostasis (15) ; furthermore, NAFLD is not only cross-sectionally associated with altered glucose tolerance and type 2 diabetes (8, 16, 17) but also predicts their development (18 -20) . Surprisingly, very few studies have evaluated the association of HbA1c levels with NAFLD, and most of them were carried out in Asian populations (8, 21, 22) , limiting their generalizability to Whites as a consequence of ethnic-related differences in HbA1c levels (23) .
Evidence has accumulated indicating that subjects with a 1-hour plasma glucose concentration during an oral glucose tolerance test (OGTT) Ն155 mg/dL (8.6 mmol/L) are at increased risk of type 2 diabetes among those who have normal glucose tolerance (24 -26) . Interestingly, individuals with 1-hour postload plasma glucose Ն155 mg/dL and normal glucose tolerance exhibit increased risk of hepatic steatosis (27) . The degree to which the recently established HbA1c diagnostic cutoff for prediabetes and 1-hour postload plasma glucose Ն155 mg/dL jointly associate with hepatic steatosis and related biomarkers remains unsettled.
To address this question, we exploited the CATAnzaro MEtabolic RIsk factors (CATAMERI) study, a large collection of Italian White adults in whom hepatic steatosis was assessed by ultrasonography (27, 28) .
Subjects and Methods
The design of the CATAMERI study has been previously described (9, 26, 27) . The study group consisted of 1108 adults who were consecutively recruited at the Department of Medical and Surgical Sciences of the University "Magna Graecia" of Catanzaro. Exclusion criteria included: history of type 1 or type 2 diabetes mellitus, end-stage renal disease, history of malignant disease, gastrointestinal diseases associated with bleeding or malabsorption, chronic pancreatitis, history of drug abuse, immunological diseases, acute infections, positivity for antibodies to hepatitis C virus or hepatitis B surface antigen, accumulation diseases such as amyloidosis and hemochromatosis, self-reporting alcohol consumption of Ͼ20 g/d, and history of treatments known to induce liver damage such as tamoxifen, glucocorticoids, tetracycline, estrogens, methotrexate, and amiodarone. All participants underwent anthropometrical evaluation including measurements of body mass index (BMI), waist circumference, body composition evaluated by bioelectrical impedance, and readings of clinic blood pressure obtained in the sitting position after 5 minutes of quiet rest. After 12-hour fasting, a 75-g OGTT was performed with 0, 30, 60, 90, and 120 minutes of sampling for plasma glucose and insulin determination.
Liver ultrasonography was performed in all participants by the same trained operator, who was blind to their clinical characteristics, using a Toshiba Aplio 50 ultrasound apparatus equipped with a 3.5-MHz linear transducer. Longitudinal, subcostal, ascending, and oblique scans were performed. The ultrasonographic criteria used to diagnose fatty liver included liver and kidney echo discrepancy, the presence of an increased liver echogenicity or "bright liver," poor echo penetration into the deep portion of the liver, and vascular blurring either singly or in combination (28) . A semiquantitative ultrasound evaluation of the degree of steatosis was not available, and therefore, subjects were categorized as having or not having liver steatosis.
The study was approved by the Hospital Ethical Committee (Comitato Etico Azienda Ospedaliera "Mater Domini"), and written informed consent was obtained from all participants in accordance with principles of the Declaration of Helsinki.
Analytical determinations
Triglyceride, total and high-density lipoprotein (HDL) cholesterol, and glucose concentrations were assayed by enzymatic methods (Roche). HbA1c was measured with HPLC using a National Glycohemoglobin Standardization Program-certified automated analyzer (Adams HA-8160 HbA1C analyzer). Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were determined using the ␣-ketoglutarate reaction, and ␥-glutamyltransferase (GGT) levels were determined with the L-␥-glutamyl-3-carboxy-4-nitroanilide rate method (Roche). Total serum IGF-1 was assayed by one-step sandwich chemiluminescence immunoassay after prior separation of IGF-1 from binding proteins on the Liaison autoanalyzer (DiaSorin), and serum insulin levels were measured with a chemiluminescence- press.endocrine.org/journal/jcem 4031 based assay (Immulite; Siemens). High-sensitivity C-reactive protein (hsCRP) levels were measured by an automated instrument (CardioPhase hsCRP). White blood cell (WBC) count was determined using an automated particle counter (ADVIA 120/2120 Hematology System; Siemens Healthcare). Fibrinogen and complement C3 were measured by an automated nephelometric technology using the BNII System analyzer (Siemens Healthcare).
Calculations
The homeostasis model of assessment for insulin resistance (HOMA-IR) index was calculated as fasting insulin ϫ fasting glucose/22.5 (29) . The liver insulin resistance (IR) index was calculated using the formula: Ϫ0.091 ϩ (log insulin AUC 0 -120 minutes ϫ 0.400) ϩ (log fat mass % ϫ 0.346) Ϫ (log HDL cholesterol ϫ 0.408) ϩ (log BMI ϫ 0.435) (30) .
Statistical analysis
Variables with skewed distribution including triglycerides; fasting, 1-hour, and 2-hour postload insulin; AST; ALT; GGT; hsCRP; and HOMA-IR were natural log transformed for statistical analyses. Continuous data are expressed as means Ϯ SD. Categorical variables were compared by 2 test. Anthropometric and metabolic differences between groups were tested after adjusting for age, gender, and BMI using a general linear model with post hoc Bonferroni correction for multiple comparisons. A multivariate logistic regression analysis was used to determine the association between the study groups and liver steatosis. A P value Ͻ.05 was considered statistically significant. All analyses were performed using IBM SPSS software program version 22.0 for Windows.
Results
The mean age of the whole study sample was 48 Ϯ 13 years; 569 subjects (51.4%) were female, and the mean BMI of the subjects was 30.2 Ϯ 6.7 kg/m 2 . Among the 1108 subjects, 343 (31.0%) were at high risk for diabetes (prediabetes) according to ADA criteria (HbA1c, 5.7-6.4%), and 54 (4.9%) were classified as having newly diagnosed type 2 diabetes (HbA1c Ն6.5%). Supplemental Table 1 displays the anthropometric features and biochemical findings of the three groups of individuals identified by the HbA1c criteria. A greater proportion of prediabetic and diabetic individuals had hepatic steatosis diagnosed by ultrasonography (Supplemental Table 1) . A logistic regression model adjusted for age and gender was used to compare the risk of prediabetic and diabetic individuals to have hepatic steatosis, as compared with the normal glucose tolerance group (Supplemental Table 1 ). Prediabetic subjects had a 1.5-fold increased risk of having hepatic steatosis; an even increased risk was observed in subjects with diabetes (2.46-fold). Accordingly, as compared with the normal glucose tolerance group, prediabetic and diabetic individuals showed significantly higher values of biomarkers of liver injury, including AST, ALT, and GGT, after adjusting for age, gender, and BMI (Supplemental Table 1 ). Moreover, as compared with the normal glucose tolerance group, prediabetic and diabetic individuals showed significantly higher values of inflammatory biomarkers including hsCRP, complement C3, and WBC count and lower levels of plasma IGF-1, a hormone produced mainly by the liver, where it exerts antiinflammatory effects (32, 33) .
HbA1c and 1-hour postload plasma glucose >155 mg/dL
A total of 595 of the 1108 participants (53.7%) had 1-hour postload plasma glucose Ն155 mg/dL. Of 54 individuals classified as having type 2 diabetes (HbA1c Ն6.5%) only two had 1-hour postload glucose Ͻ155 mg/ dL, and therefore, the diabetic group was excluded from subsequent analyses. The study cohort was divided into the following groups based on HbA1c levels and 1-hour postload plasma glucose values: 1) 421 subjects with HbA1c Ͻ5.7% and 1-hour postload plasma glucose Ͻ155 mg/dL; 2) 290 subjects with HbA1c Ͻ5.7% and 1-hour postload plasma glucose Ն155 mg/dL; 3) 90 prediabetic individuals with HbA1c of 5.7-6.4% and 1-hour postload plasma glucose Ͻ155 mg/dL; and 4) 253 prediabetic individuals with HbA1c of 5.7-6.4% and 1-hour postload plasma glucose Ն155 mg/dL. Table 1 displays the anthropometric characteristics of the four groups of individuals. Within the group with HbA1c Ͻ5.7%, individuals who had 1-hour postload plasma glucose Ն155 mg/dL were more likely to be men and to be older as compared with subjects with 1-hour postload plasma glucose Ͻ155 mg/dL. After adjusting for age and gender, individuals with 1-hour postload plasma glucose Ն155 mg/dL exhibited higher BMI and fat mass. In addition, after adjusting for age, gender, and BMI, individuals with 1-hour postload plasma glucose Ն155 mg/dL exhibited significantly higher fasting, 1-hour, and 2-hour postload glucose and insulin levels, triglycerides, uric acid, HOMA-IR index, and liver IR index and lower HDL cholesterol concentrations as compared with subjects with 1-hour postload plasma glucose Ͻ155 mg/dL (Table 2) .
Within the group with HbA1c Ͻ5.7%, a greater proportion of individuals with 1-hour postload plasma glucose Ն155 mg/dL had hepatic steatosis diagnosed by ultrasonography ( Figure 1A) . Accordingly, individuals with 1-hour postload plasma glucose Ն155 mg/dL showed significantly higher levels of AST, ALT, GGT, hsCRP, complement C3, and WBC count and lower levels of plasma IGF-1 after adjusting for age, gender, and BMI (Table 3) . In a logistic regression model adjusted for age and gender, individuals with 1-hour postload plasma glucose Ն155 mg/dL had a 1.6-fold increased risk of having hepatic ste-atosis as compared with subjects with 1-hour postload plasma glucose Ͻ155 mg/dL ( Figure 1B ).
This association remained significant when the logistic regression analysis was performed after exclusion of individuals with BMI Ͼ30 kg/m 2 . As shown in Figure 1 , C and D, individuals with 1-hour postload plasma glucose Ն155 mg/dL had a greater proportion of hepatic steatosis diagnosed by ultrasonography within the group with HbA1c Ͻ5.7% and a 1.6-fold increased risk of hepatic steatosis as compared with subjects with 1-hour postload plasma glucose Ͻ155 mg/dL.
Within the group with prediabetes (HbA1c, 5.7-6.4%), no differences in age, gender, and adiposity were observed between individuals who had 1-hour postload plasma glucose Ն155 mg/dL and those with 1-hour postload plasma glucose Ͻ155 mg/dL ( press.endocrine.org/journal/jcemwith 1-hour postload plasma glucose Ն155 mg/dL exhibited significantly higher fasting, 1-hour, and 2-hour postload glucose and insulin levels, triglycerides, uric acid, HOMA-IR index, and liver IR index and lower HDL cholesterol concentrations as compared with subjects with 1-hour postload plasma glucose Ͻ155 mg/dL, even after adjusting for age, gender, and BMI (Table 2) . Within the group with prediabetes (HbA1c, 5.7-6.4%), a greater proportion of individuals with 1-hour postload plasma glucose Ն155 mg/dL had hepatic steato- Figure 1 . A, Proportion of hepatic steatosis diagnosed by ultrasonography among individuals stratified according to HbA1c levels and 1-hour postload plasma glucose values. B, Logistic regression analyses adjusted for age and gender of the association between study group subjects and hepatic steatosis. C, Proportion of hepatic steatosis diagnosed by ultrasonography among individuals with BMI Ͻ30 kg/m 2 , stratified according to HbA1c levels and 1-hour postload plasma glucose values. D, Logistic regression analyses adjusted for age and gender of the association between study group subjects with BMI Ͻ30 kg/m 2 and hepatic steatosis. OR, odds ratio for hepatic steatosis (95% confidence interval). sis diagnosed by ultrasonography ( Figure 1A ). Accordingly, individuals with 1-hour postload plasma glucose Ն155 mg/dL showed significantly higher levels of AST, ALT, GGT, complement C3, and WBC count and lower levels of plasma IGF-1 (Table 3) . In a logistic regression model adjusted for age and gender, individuals with 1-hour postload plasma glucose Ն155 mg/dL had a 2.2-fold increased risk of hepatic steatosis as compared with subjects with 1-hour postload plasma glucose Ͻ155 mg/dL ( Figure 1B ). This association remained significant when the logistic regression analysis was performed after exclusion of individuals with BMI Ͼ30 kg/m 2 . As shown in Figure 1 , C and D, individuals with 1-hour postload plasma glucose Ն155 mg/dL had a greater proportion of hepatic steatosis diagnosed by ultrasonography within the group with HbA1c of 5.7-6.4% and had a 2.3-fold increased risk of hepatic steatosis as compared with subjects with 1-hour postload plasma glucose Ͻ155 mg/dL.
Discussion
Recently, the ADA has proposed the use of HbA1c as a diagnostic test for conditions at increased risk of diabetes (the so-called prediabetes), and a HbA1c diagnostic threshold of 5.7-6.4% (39 -46 mmol/mol) was recognized as a new indicator of conditions at increased risk of diabetes (5, 6) . Previous studies have shown that individuals with a 1-hour plasma glucose concentration during an OGTT Ն155 mg/dL (8.6 mmol/L) are at increased risk of type 2 diabetes (24 -26) . Interestingly, the addition of 1-hour plasma glucose levels during an OGTT to HbA1c values significantly increased their predictive power, with individuals having HbA1c Ͼ5.7% and 1-hour postload plasma glucose Ն155 mg/dL exhibiting a 40-fold increase in the risk of future type 2 diabetes (34). NAFLD encompasses a cluster of liver disorders characterized by hepatic fat accumulation (steatosis) in the absence of alcohol abuse and viral hepatitis, and it is often associated with features of the metabolic syndrome, including abnormal glucose tolerance/type 2 diabetes, visceral obesity, hypertension, and dyslipidemia. A number of studies have shown that NAFLD, liver biomarkers, and pro-and antiinflammatory molecules predominantly produced by the liver are associated with abnormal glucose tolerance and predict the development of type 2 diabetes (15) (16) (17) (18) (19) (20) . However, whether individuals with prediabetes diagnosed by HbA1c have increased risk of liver steatosis is presently less certain (21, 22) . Additionally, whether prediabetic individuals with HbA1c values of 5.7-6.4% and 1-hour postload plasma glucose Ն155 mg/dL are characterized by a higher risk of liver steatosis, as compared with individuals having an HbA1c value of 5.7-6.4% alone, is currently unsettled. To address this issue, we took advantage of the opportunity to study a carefully characterized cohort of 1108 individuals participating in the CATAMERI study. First, our analysis of cross-sectional data from the CATAMERI study confirmed previous observations showing that HbA1c-defined prediabetic and diabetic individuals exhibit a higher risk of having hepatic steatosis diagnosed by ultrasonography even after adjusting for age and gender, as compared with the control group. Accordingly, HbA1c-defined prediabetic and diabetic individuals display higher values of biomarkers of hepatic injury including AST, ALT, and GGT, independently from age, gender, and BMI. Additionally, prediabetic and diabetic individuals exhibit increased hepatic insulin resistance, assessed by either the HOMA-IR or the liver IR index. When we stratified our cohort into four groups based on HbA1c levels and 1-hour postload plasma glucose Ն155 mg/dL, we noted a number of interesting and original findings. We found that individuals with prediabetes (HbA1c, 5.7-6.4%) and 1-hour postload plasma glucose Ն155 mg/dL have a significantly higher risk of hepatic steatosis as compared with individuals with HbA1c-defined prediabetes but 1-hour postload plasma glucose Ͻ155 mg/dL. Accordingly, individuals with HbA1c Ͻ5.7% and 1-hour postload plasma glucose Ն155 mg/dL exhibit a significantly higher risk of hepatic steatosis as compared with individuals with HbA1c Ͻ5.7% and 1-hour postload plasma glucose Ͻ155 mg/dL. Interestingly, individuals with 1-hour postload plasma glucose Ն155 mg/dL having or not having HbA1c-defined prediabetes exhibit significantly higher postload glucose and insulin concentrations as compared with individuals with 1-hour postload plasma glucose Ͻ155 mg/dL, suggesting that postload glucose and insulin levels synergistically induce lipogenic gene expression in response to carbohydrate loads (15, 35) , leading to increased hepatic fat storage. Taken together, these data suggest that elevation in 1-hour postload plasma glucose is a major driver of hepatic steatosis, whereas HbA1c appears to play a smaller role. We found that the association between 1-hour postload plasma glucose Ն155 mg/dL and hepatic steatosis was significant in both obese (BMI Ն30 kg/m 2 ) and nonobese individuals (BMI Ͻ30 kg/m 2 ). These findings are particularly relevant in the obese individuals, given the higher prevalence of hepatic steatosis in this group. Performing an OGTT including measurement of 1-hour postload plasma glucose may be a useful tool to identify a subset of obese individuals at the highest risk of hepatic steatosis.
Moreover, individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ն155 mg/dL also exhibit an unfavorable metabolic profile characterized by doi: 10.1210/jc.2016-1856 press.endocrine.org/journal/jcem 4035 higher values of biomarkers of hepatic injury including AST, ALT, and GGT; fasting, 1-hour, and 2-hour postload glucose and insulin; triglycerides, uric acid, inflammatory biomarkers; and lower levels of HDL and IGF-1 as compared with individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ͻ155 mg/dL. There are several conceivable pathophysiological mechanisms explaining the increased risk of hepatic steatosis associated with 1-hour postload plasma glucose Ն155 mg/ dL. We have recently shown that individuals with 1-hour postload plasma glucose Ն155 mg/dL exhibit higher dietary intake of saturated fatty acids and fructose (36) . Because about 15% of triacylglycerol content in the liver of patients with NAFLD originates from dietary fatty acids, it is plausible that increased fat intake may contribute to increased risk of hepatic steatosis associated with 1-hour postload plasma glucose Ն155 mg/dL. Likewise, fructose stimulates hepatic de novo lipogenesis and is also a source of uric acid, which can in turn directly stimulate hepatic fat accumulation (37) . Accordingly, we observed that individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ն155 mg/dL exhibit higher levels of uric acid as compared with individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ͻ155 mg/dL. Furthermore, there is evidence that hyperuricemia might be partially responsible for the severity of histological liver damage in subjects with NAFLD (38) . It is possible that uric acid may induce liver damage by favoring an unpaired balance between proinflammatory and anti-inflammatory proteins such as IGF-1 (33) . In fact, there is evidence that uric acid induces expression of proinflammatory molecules while impairing GH-stimulated expression of IGF-1 in human hepatoma cells (39, 40) . In agreement with these in vitro data, we observed that individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ն155 mg/dL exhibit higher levels of inflammatory markers and lower levels of plasma IGF-1 as compared with individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ͻ155 mg/dL.
Glucose has been shown to regulate lipogenic gene transcription by activating carbohydrate-responsive element-binding protein. High glucose concentrations induce dephosphorylation of carbohydrate-responsive element-binding protein, resulting in its translocation into the nucleus where it activates lipogenic target genes. Furthermore, glucose is known to be a major source of acetyl coenzyme A and provides the carbon for fatty acid synthesis in the liver. Thus, it is conceivable that excessive glucose elevation after a meal may activate hepatic lipogenic gene transcription, resulting in hepatic steatosis.
Finally, individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ն155 mg/dL have higher levels of HOMA-IR and liver IR index, two validated proxies of hepatic insulin resistance (29 -31) , as compared with individuals with HbA1c-defined prediabetes and 1-hour postload plasma glucose Ͻ155 mg/dL. Hepatic insulin resistance, which is thought to be a core component of NAFLD (15) , is characterized by a selective defect in the capability of insulin to suppress glucose production while the ability to stimulate lipogenesis is maintained, thus resulting in increased synthesis of fatty acids and triglycerides (15) .
Taken together, these results support the idea that 1-hour postload plasma glucose Ն155 mg/dL may be a useful glycemic parameter for identifying a subset of individuals with HbA1c-defined prediabetes harboring the highest risk of developing hepatic steatosis and its related metabolic abnormalities and who may benefit most from lifestyle or pharmacological interventions (2, 3) . Furthermore, our results may provide the basis for future clinical studies aimed at evaluating the effect of glucose-lowering interventions in individuals with 1-hour postload hyperglycemia on the risk of developing hepatic steatosis. In fact, keeping in mind the link between high glucose concentrations and hepatic accumulation of fatty acid, it is possible to hypothesize that the correction of postload hyperglycemia may counteract the increased synthesis of fatty acid in the hepatocytes and consequently prevent the development of hepatic steatosis.
The current study has a number of strengths, including the large sample size encompassing both men and women, the detailed anthropometric and biochemical data collected according to a standardized protocol by trained staff, the centralization of biochemical analyses comprising a rigorously standardized HbA1c measurement, the assay of metabolites and hormones in fresh blood samples rather than in stored samples that may be subject to degradation, the ultrasound diagnosis of NAFLD performed by an experienced examiner who was blinded to the subjects' clinical and biochemical data, the use of a restrictive post hoc Bonferroni test to correct for multiple comparisons, and the exclusion of confounding conditions characterized by liver damage such as heavy drinking, accumulation diseases, or positivity for antibodies to hepatitis C virus or hepatitis B surface antigen.
Nonetheless, some limitations of our study merit comment. First, the evaluation of each metabolic variable, including HbA1c and OGTT, has been performed once, and small day-to-day changes would be expected. Although such an approach is common in both clinical practice and epidemiological studies, the intraindividual variability of glucose homeostasis parameters cannot be taken into ac-count, and this may have introduced some imprecision in the categorization of participants into the dysglycemic categories. Second, the diagnosis of hepatic steatosis was based on ultrasonography rather than on invasive methods such as percutaneous liver biopsy. However, although its sensitivity is suboptimal when hepatic fat infiltration of the liver is Ͻ30%, ultrasonography is the common method of diagnosing hepatic steatosis in clinical practice and epidemiological studies. Additionally, all participants in the present study were White, and whether our results can also be extended to other ethnic groups remains to be established. Furthermore, the information on alcohol intake was assessed by self-reported questionnaire; thus, the actual daily alcohol consumption may have been underestimated. Finally, the cross-sectional design of the study reflects only an association with prevalent liver steatosis and precludes us from drawing any conclusion about causal relationships between dysglycemic conditions assessed by HbA1c and liver fat accumulation.
